Healthcare >> CEO Interviews >> August 27, 2014

Interview with the Founder, CEO and Chairman and the Chief Strategy Officer: Immune Pharmaceuticals Inc. (IMNP)

Hehenberger, Karin
Dr. Karin Hehenberger is the Chief Strategy Officer of Immune Pharmaceuticals Inc., and is responsible for managing the company’s relationships with medical opinion leaders and patient organizations, in addition to being part of the team handling media and investors. Dr. Hehenberger has more than 15 years’ experience in the life sciences industry, and was most recently the Executive Vice President, Scientific Affairs and Chief Medical Officer at Coronado Biosciences, prior to which she held senior leadership positions at the Juvenile Diabetes Research Foundation, or JDRF; Johnson & Johnson; Eyetech Pharmaceuticals; and at public and private investment funds. She started her career at McKinsey & Co., and received her M.D. and Ph.D. from the Karolinska Institute in Sweden. She also completed a postdoctorate at Harvard Medical School. Profile
Teper, Daniel
Dr. Daniel Teper is the Founder, CEO and Chairman of Immune Pharmaceuticals Inc. Dr. Teper was the Managing Director for North America at Bionest Partners, a global strategy consulting firm advising pharmaceutical and public biotechnology companies, and previously a New York-based Partner at ISO Healthcare Consulting — now part of Deloitte Monitor Group. Dr. Teper started his career at Novartis global headquarters in Basel and then in the United States, where he had growing responsibilities in sales, marketing and new product development. He held senior executive positions in Europe, first at GSK as Head of Commercial Operations for Glaxo France, and then as President and Chief Operating Officer of Laboratoires Delagrange through the acquisition by Synthelabo — now part of Sanofi. He then became President of Global Operations at Havas Healthcare Worldwide, a leading marketing and communication group, where he helped launch multiple industry blockbusters. Dr. Teper was a co-founder of Novagali (NOVA), which was acquired by Japan’s Santen. Dr. Teper holds a Doctor of Pharmacy degree, or PharmD, from Paris XI University and an MBA from INSEAD. Profile
TWST: Can you provide an overview of the company and talk about what drove you to start the company?

Dr. Teper: Immune Pharmaceuticals is a biopharmaceutical company listed on Nasdaq